Lucentis (Microvascular Complications of Diabetes) Industry Analysis & Report

1
Lucentis (Microvascular Complications of
Diabetes) Forecast and Market Analysis to
2022byGlobalData

• Explore all reports for  Diabetes Therapeutics
  market
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/therapeutics/diabetes-therape
  utics .

2
Lucentis (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• The entire market for microvascular complications
  of diabetes (MCD) diabetic nephropathy,
  retinopathy, and neuropathy is facing an
  extremely high level of unmet need across the 7MM
  (US, 5EU and Japan). Despite its enormous
  potential, the MCD market is facing the major
  global barrier in the sparsely populated
  pipeline. The diabetic retinopathy segment of the
  market has recently seen rapid uptake of novel
  anti-VEGF therapies and is experiencing a strong
  growth. On the other hand, the diabetic
  neuropathy and nephropathy segments face the
  barrier in and increasing number of generic
  competitors.
• Lucentis (ranibizumab) is a humanized fragment
  antigen-binding(Fab) fragment of an
  immunoglobulin G1 (IgG1) monoclonal antibody
  (mAb) that specifically binds to all isoforms of
  vascular endothelial growth factor (VEGF)-A,
  thereby preventing the binding of VEGF-A to its
  vascular endothelial growth factor receptor
  (VEGFR)-1 and (VEGFR-2) (Bandello et al., 2012).
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147159 .

3
Lucentis (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• Scope
• Overview of MCD, including epidemiology,
  etiology, symptoms, diagnosis, pathology and
  treatment guidelines as well as an overview on
  the competitive landscape.
• Detailed information on Lucentis including
  product description, safety and efficacy profiles
  as well as a SWOT analysis.
• Sales forecast for Lucentis for the top seven
  countries from 2012 to 2022.
• Sales information covered for the US, France,
  Germany, Italy, Spain, the UK and Japan.
• Complete report available _at_ http//www.rnrmarketre
  search.com/lucentis-microvascular-complications-of
  -diabetes-forecast-and-market-analysis-to-2022-mar
  ket-report.html .

4
Lucentis (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• Reasons to buy
• Understand and capitalize by identifying products
  that are most likely to ensure a robust return
• Stay ahead of the competition by understanding
  the changing competitive landscape for MCD
• Effectively plan your MA and partnership
  strategies by identifying drugs with the most
  promising sales potential
• Make more informed business decisions from
  insightful and in-depth analysis of Lucentis
  performance
• Obtain sales forecast for Lucentis from 2012-2022
  in top seven countries (the US, France, Germany,
  Italy, Spain, the UK and Japan)
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147159 .

5
Lucentis (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• Table Of Contents
• 1 Table of Contents1 Table of Contents 61.1
  List of Tables 81.2 List of Figures 8
• 2 Introduction 92.1 Catalyst 92.2 Related
  Reports 10
• 3 Disease Overview 123.1 Etiology and
  Pathophysiology 143.1.1 Diabetic Nephropathy
  143.1.2 Diabetic Retinopathy 163.1.3 Diabetic
  Neuropathy 173.2 Prognosis 183.3 Quality of
  Life 193.4 Symptoms 20
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147159 .

6
Lucentis (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• 4 Disease Management 214.1 Treatment Overview
  214.1.1 Diagnosis and Referrals 214.1.2
  Screening 234.1.3 Treatment Guidelines 24
• 5 Competitive Assessment 325.1 Overview 325.2
  Strategic Competitor Assessment 33
• 6 Lucentis (ranibizumab) 376.1 Overview 376.2
  Efficacy 396.3 Safety 406.4 SWOT Analysis
  416.5 Forecast 41
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147159 .

7
Lucentis (Microvascular Complications of
Diabetes) Forecast and Market Analysis to 2022

• 7 Appendix 437.1 Bibliography 437.2
  Abbreviations 487.3 Methodology 517.4
  Forecasting Methodology 517.4.1 Diagnosed
  Patients 517.4.2 Percent Drug-Treated Patients
  527.4.3 General Pricing Assumptions 527.4.4
  Individual Drug Assumptions 537.4.5 Generic
  Erosion 537.5 Physicians and Specialists
  Included in this Study 547.6 About the Authors
  567.6.1 Analyst II - CVMD 567.6.2 Therapy
  Director - CVMD and Infectious Disease 567.6.3
  Global Head of Healthcare 577.7 About GlobalData
  587.8 Disclaimer 58
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147159 .

8
China nuclear power generation industry, 2014

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.